Alzheimer's Disease clinical trials in Indiana
19 active Alzheimer's Disease trials with a site in Indiana. Describe your situation to see which ones you may be eligible for.
- A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- Nicotinic Acid for the Treatment of Alzheimer's Disease
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- Trial-Ready Cohort-Down Syndrome (TRC-DS)
- Dominantly Inherited Alzheimer Network (DIAN)
- Alzheimer's Disease Genetics Study
- Late Onset Alzheimer's Disease
- Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
- I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
- A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
- Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease
- Alzheimer's Disease Neuroimaging Initiative 4
- The Diabetes Prevention Program Outcomes Study AD/ADRD Project
- A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
- Longitudinal Early-onset Alzheimer's Disease Study Protocol
- I-CARE Rural Pilot: Intervention for Rural-Dwelling Dementia Caregivers
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.